Euphon (+Codeine)

Quick links to important sections

Euphon (+Codeine)

Selected form

Method of action: Throat Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Euphon (+Codeine)

Quick Facts

Property Description
Active Ingredients Codeine, Erysimum officinale (Hedge Mustard extract)
Form Oral Solution / Syrup
Pharmacological Class Central Antitussive & Pharyngeal Emollient
General Purpose Relief of dry, irritating coughs and vocal discomfort
Origin Semi-synthetic and Natural-source combination

Defining Euphon (+Codeine): Class and Composition

Euphon (+Codeine) is a fixed-dose combination product containing the opioid alkaloid codeine and a phytotherapeutic extract of Erysimum officinale (Hedge Mustard). This combination positions it as both a central antitussive (cough suppressant) and a pharyngeal emollient (soothing agent).

Pharmacologically, the preparation integrates the systemic activity of codeine, a well-recognized phenanthrene alkaloid whose action is to elevate the cough threshold in the central nervous system. This distinguishes it from cough remedies acting only locally. The inclusion of Erysimum officinale defines its secondary, local action, providing a demulcent property to soothe and protect the mucous membranes of the throat.


Dual Origin and Dosage Format

This medication features a dual origin, integrating a semi-synthetic component (codeine, derived from opium) with a natural-source element (Erysimum officinale extract). The primary commercial format is an oral solution or syrup, intended for the oral route of administration.

The liquid format is strategically designed for effective delivery. During swallowing, the syrup allows the demulcent properties of the Erysimum officinale to physically coat the pharynx and larynx, maximizing its local emollient effect. This herbal component is clinically recognized for its benefit to the voice, particularly in cases of hoarseness. The combination is typically designated as a prescription-only medication in countries like France due to the controlled substance status of codeine.


General Purpose: Addressing Cough and Vocal Irritation

The general purpose of Euphon (+Codeine) is to provide comprehensive relief for persistent, dry, and irritating coughs often accompanied by concurrent throat discomfort, such as those that may occur after a respiratory infection. The strong antitussive action from the codeine component helps control the frequency and intensity of disruptive coughing.

Simultaneously, the Erysimum officinale component serves to specifically support the irritated tissues of the throat and vocal cords. This local action is highly relevant when a cough is associated with hoarseness, vocal strain, or mild laryngitis, where the emollient properties help to protect the phonatory function, reducing soreness and contributing to the restoration of vocal clarity.

Regulatory References

  1. Notice patient - EUPHON, sirop - ANSM

What side effects are possible with Euphon (+Codeine)?

Possible side effects and safety information

This section outlines the officially documented adverse effects and safety characteristics of this medication, which are primarily attributed to the systemic action of the opioid component, codeine, as documented in government regulatory sources.

Category Description
Key adverse reaction categories Systemic effects dominated by codeine (opioid-related) and localized/mild systemic effects from the Erysimum officinale extract.
Frequency classification Common effects listed in regulatory documents include drowsiness, constipation, nausea, and vomiting (Nervous System and Gastrointestinal Disorders). Respiratory depression is classified as a rare but serious reaction.
Serious adverse reactions Life-Threatening Respiratory Depression and the potential for Opioid Dependence and Withdrawal Syndrome associated with prolonged use are highlighted in official warnings.
Population-specific safety considerations The medicine is contraindicated in children under 12 years of age and in breastfeeding mothers; dose adjustments are typically required for older adults and patients with hepatic or renal impairment.
Safety-related restrictions or limitations Contraindicated in individuals identified as CYP2D6 ultra-rapid metabolizers due to the increased risk of toxicity from rapid morphine conversion, as well as in patients with acute respiratory failure or severe hepatic dysfunction.

Time- and Context-Related Safety Patterns

Regulatory safety information specifies that the greatest risk of respiratory depression is at the start of treatment or following an increase in dose. The concomitant use of this medicine with other Central Nervous System (CNS) depressants (e.g., alcohol or sedating antihistamines) is officially noted to significantly increase the risk of severe safety outcomes, including enhanced sedation and profound respiratory depression. The potential for opioid dependence is linked to long-term exposure to the medication.

Overdose and Emergency Response

Euphon (+Codeine) Overdose and when to seek help

Overdose of this product is classified as a medical emergency primarily due to the severe effects of its codeine component on the central nervous and respiratory systems.

Documented Clinical Manifestations

A suspected overdose may present with signs of profound central nervous system (CNS) depression, including extreme drowsiness, confusion, loss of consciousness, or coma. Regulator-documented physical signs include pinpoint pupils (miosis), cold/clammy skin, and hypotension (low blood pressure). The most critical sign is life-threatening respiratory depression, characterized by shallow, slow, or absent breathing, which can lead to cyanosis (bluish skin/lips).

Severe Outcomes and Immediate Action

Official regulatory documents state that overdose can result in shock, brain damage, and death. Due to these risks, regulatory authorities mandate that any suspected overdose requires immediately contacting emergency services or the national Poison Help hotline. Immediate medical attention must be sought, and the medicine must be discontinued at once.

Overdose Management and Specific Considerations

Management focuses on symptomatic and supportive treatment, including necessary breathing support (e.g., mechanical ventilation). The specific antidote, Naloxone, is described as the medicine used to reverse the opioid's depressive effects. A specific warning is documented regarding children, where accidental ingestion of even one dose can result in a fatal overdose, underscoring the population-specific high risk.

Therapeutic Uses of Euphon (+Codeine)

What Euphon (+Codeine) Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed for symptom clusters related to physical discomfort, such as persistent, non-productive coughs that are irritating and disruptive, like those that may intensify following a respiratory infection. Codeine is commonly used to help with cough. It generally provides symptomatic relief by managing symptoms related to increased neurological or muscular activity, contributing to easing the overall symptom load by helping manage the frequency and intensity of these episodes, which may assist with maintaining functional stability.

The formula is relevant when symptoms related to inflammatory or irritative states occur with coughing, including symptoms like soreness and hoarseness (dysphonia). It provides supportive therapeutic benefit, as it may assist with easing the overall symptom load, contributes to improved comfort during periods of heightened symptoms by easing the symptom load on the throat, and supporting patients during episodes of heightened discomfort.

“This preparation may assist with easing the overall symptom load by addressing symptoms that interfere with daily functioning and symptoms related to inflammatory or irritative states.”

Quick Fact: Support for Symptom Clusters
Main Symptom Domain Persistent, non-productive dry cough.
Associated Symptoms Soreness, hoarseness (dysphonia), and throat irritation.
Primary Benefit Helps control frequency and intensity; supports general well-being during symptomatic phases.
Common Scenario Managing symptoms that disrupt sleep or linger post-respiratory infection.

Regulatory References

  1. According to the NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Euphon (+Codeine)?

Eligibility for Euphon (+Codeine) is strictly governed by the population restrictions established for its opioid component, codeine, as documented by official regulatory agencies like the FDA and EMA. Use is permitted only in adults without contraindications.


Absolute Contraindications

Official labeling prohibits the use of this medicine in several populations due to safety risks:

  • Children younger than 12 years of age for any indication.
  • Breastfeeding women due to the risk of serious infant respiratory depression.
  • Patients of any age who are CYP2D6 ultra-rapid metabolizers.
  • Patients with significant respiratory depression or acute/severe bronchial asthma.
  • Patients with known gastrointestinal obstruction (e.g., paralytic ileus).

Restricted and Conditional Use

  • Adolescents (12–18 years): Use is generally not recommended in those with compromised respiratory function (e.g., obesity or severe lung disease).
  • Post-Surgery: Contraindicated for use in children under 18 following tonsillectomy and/or adenoidectomy.
  • Pregnancy: Use may cause fetal harm (Neonatal Opioid Withdrawal Syndrome), and is generally advised to be avoided.
  • Organ Function: Patients with hepatic or renal impairment must be monitored closely, as codeine is metabolized by the liver and eliminated by the kidneys.
  • Older Adults: Require close monitoring due to increased susceptibility to respiratory depression.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The codeine component of this product is subject to numerous drug interactions that can lead to severe adverse outcomes, including fatal respiratory depression or reduced efficacy.

Interacting Product Category Regulatory Statement
CNS Depressants (e.g., Benzodiazepines, Alcohol) Concomitant use is associated with profound sedation, respiratory depression, coma, and death. Prescribing should be limited to the minimum required dosage and duration when alternative treatments are inadequate.
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use is contraindicated, or within 14 days of stopping an MAOI, due to the potential for potentiated effects like respiratory depression or Serotonin Syndrome.
CYP2D6 Inhibitors (e.g., Quinidine) These may decrease the conversion of codeine to its active metabolite, morphine, which can result in reduced analgesic effect or symptoms of opioid withdrawal. Dose adjustment and close patient monitoring are necessary.
CYP3A4 Inhibitors/Inducers Use with agents that inhibit or induce CYP3A4 (e.g., macrolides, ritonavir) can cause complex changes in codeine and morphine plasma concentrations. Close monitoring for increased side effects or reduced efficacy is required.
Opioid Mixed Agonists/Partial Agonists Concurrent use (e.g., buprenorphine, nalbuphine) should be avoided as they may reduce the product's analgesic effect or precipitate withdrawal symptoms.

Regulatory agencies prohibit the use of codeine in children younger than 12 years of age and in adolescents younger than 18 years following tonsillectomy and/or adenoidectomy, due to metabolism-related risks.

Mechanism of Action

How Euphon (+Codeine) Works

This fixed-dose combination modulates the cough reflex through two distinct biological mechanisms: central suppression and peripheral sensory input modulation.


Central Modulation of the Cough Reflex Threshold

This domain covers the systemic action of codeine, which acts as an agonist at μ-opioid receptors (μ-OR) within the medulla oblongata (the brain's cough center). This interaction inhibits neuronal excitability, leading to an elevated cough threshold. This core mechanism modifies the central nervous system's responsiveness, fundamentally reducing the motor output signal that triggers the involuntary cough.


Peripheral Barrier Function and Sensory Input Reduction

This domain focuses on the local, physical action of the Erysimum officinale extract on the pharyngeal and laryngeal mucous membranes. Mucilaginous compounds form a protective physical barrier (demulcent action), which forms a physical barrier between mucosal tissue and external stimuli. This mechanism reduces the stream of afferent signals (irritation input) sent from the throat to the CNS, reducing the influence of afferent input on the central cough center.


Mechanistic Synergy and Receptor Engagement Determinants

The drug exerts a complementary dual action, with the central mechanism reducing output and the peripheral mechanism reducing input to the cough reflex arc. The magnitude of μ-opioid receptor engagement is dependent on the body's conversion of codeine to its active metabolite via the CYP2D6 enzyme; individuals with low enzyme activity exhibit reduced μ-opioid receptor agonism.

Dosage and Administration Information

The administration of Euphon (+Codeine) is strictly limited to the oral route as a syrup or oral solution. The use is structured around an as-needed protocol for a short duration of only a few days, and it is explicitly constrained to periods when a non-productive (dry) cough occurs.


Dosage and Frequency

Standard administration for adults and adolescents aged 15 years and older (weighing 50 kg or more) is one to two doses of 15 mL per intake. Each 15 mL dose contains 15 mg of codeine, meaning a single intake delivers 15 mg to 30 mg of the antitussive component. Doses must be separated by a minimum interval of six hours and must not exceed four doses per day.

Administration Parameter Instruction
Route Oral use only.
Minimum Interval Six hours between doses.
Daily Maximum Not to exceed four doses.
Duration Limited to short duration (a few days).

Administration Context and Adjustments

The precise dose must be measured using the graduated cup or measuring device provided with the bottle. The instructions emphasize that the medicine is only to be administered when necessary, suggesting a single evening dose may be sufficient if the cough is primarily nocturnal. Furthermore, specific high-level dose reductions are required for certain patient populations to adhere to safety limits. Doses for elderly patients must be reduced by half compared to the standard adult regimen. This half-dose reduction also applies to the initial treatment phase for patients identified with hepatic impairment, a rule consistent across codeine-containing product labels. Use is restricted to individuals aged 12 years and older (weighing 40 kg or more), with a separate 10 mL dose defined for the 12–15 year-old group. The medicine must not be used in combination with an expectorant or mucolytic.

Recent Clinical Evidence

Evidence for the Antitussive Component: Research on Dry Cough

Research has explored the component codeine in trials assessing short-term or episodic symptom patterns. The study designs often included short-term Randomized Controlled Trials (RCTs) where the component was evaluated against an inactive substance (placebo). Outcomes describing episodic changes were monitored, such as measurements of cough frequency and patient-reported scores.

For acute cough following respiratory infections, studies report patterns of how symptoms changed. Findings from these comparisons were mixed; research highlights that measured symptom changes varied across reports, particularly where the measured outcomes did not consistently show certain changes when compared against placebo. Evidence contributes to the broader landscape, however, it is important to note that study results reflect the specific conditions under which they were conducted.

Studies for Acute vs. Chronic Cough

Studies focusing on acute cough concentrated on very short observation periods. In contrast, for chronic cough, studies often involved observing symptoms in daily-life functioning. Findings from these non-trial settings contribute to understanding symptom patterns as patients reported their experience over defined time intervals.

Evidence for the Emollient Component: Studies on Vocal and Throat Discomfort

The plant-derived emollient component (Erysimum officinale) was studied in research contexts involving unstable symptoms, such as hoarseness or dysphonia. This research primarily utilized small-group patient studies examining patient-reported experiences. Outcomes related to physical discomfort in the throat were explored. Findings from these smaller studies reported changes measured during the study period regarding the patient’s vocal status and perceived disability. Data for this component are still emerging, and research is ongoing, with current evidence derived from traditional applications that require further scientific validation.

Areas of Research Uncertainty and Study Gaps

Key limitations in the research frame include modest sample sizes and follow-up durations that were limited. There is limited information for long-term outcomes, and the durability of any reported short-term changes is not fully established. Subgroup findings are uncertain, as comparative evidence is lacking for many patient groups. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Euphon (+Codeine) (FAQ)

Q: What is the main difference between Euphon and Euphon (+Codeine) formulations?

A: According to the official product information, Euphon (+Codeine) is a fixed-dose combination that includes both the Erysimum officinale extract and the central cough suppressant, codeine. The primary difference is the inclusion of codeine, which acts as a central cough suppressant. The standard Euphon product generally contains only the Erysimum officinale extract for local soothing relief.

Q: Is Euphon (+Codeine) considered a narcotic or controlled substance?

A: Due to the presence of codeine, the product is classified as a controlled substance under national regulations in many markets. Due to its classification as a controlled substance, the medicine is typically designated as prescription-only in many markets.

Q: Does Euphon (+Codeine) help with throat irritation as well as cough symptoms?

A: Yes, official product information describes the medicine's purpose as comprehensive relief for dry, irritating coughs and associated throat discomfort. This dual benefit comes from the codeine component suppressing the cough and the Erysimum officinale extract providing a soothing, local action on the throat's mucous membranes.

Q: Why is codeine included in this particular cough medicine formulation?

A: Codeine is included specifically to provide central antitussive activity. Its main function is to elevate the cough reflex threshold within the brain’s cough center. This action works systemically to reduce the frequency and intensity of disruptive coughing.

Q: What is the non-codeine component of Euphon (+Codeine) intended to do?

A: The Erysimum officinale extract is intended to act locally as a pharyngeal emollient. Its purpose is to form a protective physical barrier over the mucous membranes of the throat. This demulcent action helps to soothe irritation and reduces the sensory input that triggers the central cough reflex.

Q: What are the official warning signs of a serious allergic reaction to Euphon (+Codeine)?

A: Regulatory documents list severe hypersensitivity as a possible adverse effect. Signs of a serious allergic reaction can include rash, severe itching, swelling of the face, tongue, or throat, or significant difficulty breathing. If these signs are observed, immediate medical attention is necessary.

Q: Why do regulatory documents emphasize warnings about potential breathing problems with codeine?

A: Codeine acts as an opioid agonist in the central nervous system (CNS), and this action can inhibit the part of the brain that controls breathing. This effect is known as respiratory depression, which causes breathing to become slow or shallow. Regulatory agencies emphasize this risk, particularly at the start of treatment or following a dose increase.

Q: How long does the main effect of Euphon (+Codeine) usually last after a single dose?

A: While the exact duration of the perceived effect is not specified, official dosing instructions require a minimum interval of six hours between doses. This minimum interval suggests that the primary antitussive effect is expected to last for a duration of up to six hours.

Q: Is it normal if a person does not feel a noticeable change after taking Euphon (+Codeine)?

A: Official information indicates that the effectiveness of codeine can vary significantly between people. This is because the drug's effectiveness depends on the activity of the CYP2D6 enzyme. People with low activity of this enzyme may experience a reduced or unnoticeable effect.

Q: Does the effectiveness of Euphon (+Codeine) vary widely between different people?

A: Yes, official regulatory information confirms that effectiveness can vary widely. This variation is primarily due to differences in a person's CYP2D6 enzyme activity. This enzyme is crucial for metabolizing codeine into its active form.

Q: What safety profile information exists for young adults taking Euphon (+Codeine)?

A: Young adults (aged 18 and older) are generally managed under the standard adult dosing regimen, as long as no contraindications exist. Official safety warnings focus on dose-related risks and interactions, emphasizing that all adults are susceptible to serious side effects like respiratory depression.

Q: Can Euphon (+Codeine) be taken by people who manage blood sugar levels?

A: As an oral solution or syrup, this product may contain excipients like sugar or sweeteners, which could impact blood sugar levels. Patients who are managing their blood sugar should consult the official excipients list provided in the regulatory label for precise content information.

Q: Is Euphon (+Codeine) available over-the-counter in any regulatory markets?

A: The legal status of the medicine is determined by the national drug scheduling laws of each country. Because it contains codeine, it is commonly classified as a controlled substance and is designated as prescription-only or requiring specific pharmacy guidance in many regulatory markets.

Q: How long after taking Euphon (+Codeine) should a person generally wait before driving or operating machinery?

A: Official guidance warns that this medicine may cause common side effects such as drowsiness, dizziness, and reduced alertness. Official guidance cautions against driving or operating machinery until the patient knows how the medicine affects their ability to perform these tasks safely.

Q: Can Euphon (+Codeine) cause difficulty falling asleep or staying asleep?

A: While common side effects include drowsiness and sedation, regulatory lists of opioid adverse effects may also include insomnia (difficulty sleeping) or restlessness. Difficulty falling asleep or restlessness may be noted as possible, though less common, effects in regulatory documentation.

Q: Are there any known long-term side effects from occasional use of Euphon (+Codeine)?

A: Official documentation specifically focuses on the potential for dependence and withdrawal syndrome associated with long-term exposure to the medicine. Information detailing specific side effects resulting from occasional, non-chronic use over an extended period is not typically detailed in regulatory labels.

Q: Does Euphon (+Codeine) contain common allergens like gluten, dairy, or sulfites?

A: Regulatory documents list all inactive ingredients, or excipients, which may include materials like sulfites. Confirming the presence of specific allergens like gluten or dairy requires reviewing the full excipients list for the specific formulation.

Q: Is it possible to feel dizzy or unsteady after taking a standard dose of Euphon (+Codeine)?

A: Yes, regulatory documentation lists dizziness or vertigo as a known adverse reaction associated with the systemic action of codeine. This effect is related to the drug's influence on the central nervous system.

Q: Can Euphon (+Codeine) potentially make existing stomach discomfort worse?

A: Common side effects include constipation, nausea, and vomiting. Due to codeine reducing movement in the gastrointestinal tract, there is a potential for symptoms related to pre-existing stomach or bowel conditions to be affected.

Q: Does Euphon (+Codeine) affect mood or anxiety levels, according to official data?

A: Official lists of adverse reactions for opioids can include psychiatric disorders. These may encompass feelings of confusion, restlessness, or changes in mood, which could potentially include alterations in anxiety levels. Such effects are generally considered less common.

Q: What is the recommended action if someone forgets to take a dose of Euphon (+Codeine)?

A: Regulatory guidance generally addresses missed doses by stating that patients should not take a double dose to compensate. It is important to maintain the minimum six-hour interval before the next dose.

Q: Does Euphon (+Codeine) interact with common dietary supplements or foods?

A: Regulatory documents may include warnings about certain substances, such as grapefruit juice or St. John's Wort, as these can affect the CYP enzyme activity involved in codeine metabolism.

Q: What is the official information regarding Euphon (+Codeine) and people with high blood pressure?

A: While high blood pressure is not typically an absolute contraindication, official warnings for codeine may include caution for patients with certain cardiovascular conditions or those using anti-hypertensive drugs. This is due to the potential for the drug to cause minor changes in heart rate or blood pressure.

Q: Can taking Euphon (+Codeine) change the color or odor of urine?

A: Changes in the appearance of urine, such as discoloration, are sometimes listed in regulatory documentation as a possible, though rare, adverse effect associated with certain opioid-containing medicines.

Q: Does Euphon (+Codeine) interact with non-prescription cold and flu medicines containing acetaminophen?

A: No direct interaction with acetaminophen (paracetamol) is expected. However, the regulatory warning about concurrent use with other central nervous system (CNS) depressants means caution is necessary if the cold or flu medicine contains sedating antihistamines or other depressants.

Q: Can a person consume caffeine or coffee while taking Euphon (+Codeine)?

A: Regulatory documentation does not typically list caffeine as a direct drug interaction. However, because codeine commonly causes drowsiness, caffeine consumption may mask this sedative effect. The risk of CNS depression remains if the medicine is combined with other sedating agents.

Q: Is it safe to take Euphon (+Codeine) alongside common herbal remedies or supplements?

A: Official warnings caution against combining codeine with substances that affect the CYP2D6 enzyme. Reviewing concurrent products with a healthcare provider can help manage potential changes in effectiveness or side effects, particularly if the supplements are enzyme inhibitors.

Q: Does Euphon (+Codeine) have interactions with common medicines used for depression or anxiety?

A: Official regulatory information warns against concurrent use with Central Nervous System (CNS) depressants. Certain antidepressants are strictly contraindicated, and reviewing all mood-altering medicines with a healthcare provider is important to avoid potential interactions.

Q: Can Euphon (+Codeine) be used at the same time as common over-the-counter painkillers like ibuprofen?

A: Official regulatory documents do not typically list a direct contraindication with non-opioid, non-CNS depressant painkillers like ibuprofen. The primary interaction concern centers on avoiding other medicines that may cause profound sedation or respiratory depression.

Q: Does smoking or nicotine consumption affect how Euphon (+Codeine) is processed by the body?

A: Nicotine can be an enzyme inducer. Regulatory pharmacokinetic information may suggest that smoking could affect the activity of the CYP enzymes responsible for metabolizing codeine. This could potentially lead to changes in how the medicine is metabolized.

Q: How quickly does Euphon (+Codeine) typically start working to relieve cough symptoms?

A: Official pharmacokinetic data for codeine suggests that the peak concentration of the drug in the bloodstream typically occurs approximately one to two hours after intake. This peak concentration generally correlates with the time of maximum central antitussive effect.

Q: What does official guidance say about using Euphon (+Codeine) past its expiration date?

A: Official regulatory guidance states that all medicines must not be used past the expiration date printed on the packaging. The expiration date is set by the manufacturer to ensure the drug maintains its stability, potency, and safety up to that date.

Q: How long does the codeine component of Euphon (+Codeine) stay detectable in the system?

A: Regulatory pharmacokinetic data for codeine generally cites a terminal half-life of two to four hours. Based on standard elimination principles, the active components of the drug are largely removed from the system within several half-lives after the last dose.

Q: What is the expected appearance and odor of Euphon (+Codeine) syrup?

A: The official regulatory documents include a description of the medicine's expected physical properties. It is typically described as a clear or slightly viscous solution, often having a specific color and odor that are characteristic of its ingredients.

Q: Does Euphon (+Codeine) interact with medicines for acid reflux or heartburn?

A: Official regulatory documents do not typically list a direct interaction between codeine and common acid reflux or heartburn medicines. Interaction concerns are usually limited to medications that could affect codeine's metabolism or increase central nervous system depression.

Q: Is Euphon (+Codeine) suitable for people who have a known enzyme deficiency?

A: The product is strictly contraindicated for individuals who are known CYP2D6 ultra-rapid metabolizers. Patients identified as poor metabolizers may also experience reduced efficacy or different side effect profiles due to the altered conversion of codeine to its active metabolite.

Q: Can Euphon (+Codeine) be used by people with a history of asthma or COPD?

A: The medicine is contraindicated for use in patients experiencing severe bronchial asthma or acute respiratory failure. Official guidance indicates that individuals with a history of chronic respiratory conditions may require careful monitoring.

Q: What does the research say about the non-codeine ingredients in Euphon (+Codeine)?

A: Research on the Erysimum officinale component typically involves smaller, patient-focused studies examining reported relief for symptoms like hoarseness or dysphonia. Official information often notes that while findings contribute to a broader understanding, the evidence derived from traditional applications requires further scientific validation.

Q: Are there common signs that Euphon (+Codeine) is starting to wear off?

A: The primary indicator that the antitussive effect is diminishing is the return of the dry, irritating cough the medicine was intended to manage. The recurrence of this disruptive cough signals that the next dose may be necessary, provided the minimum six-hour interval has elapsed.

How should Euphon (+Codeine) be stored and disposed of?

How to Store and Dispose of Euphon (+Codeine)?

The storage and disposal of Euphon syrup, which contains the controlled substance codeine, must adhere strictly to regulatory requirements to ensure stability and public safety.

Storage Requirements

The medicine must be stored at controlled room temperature, typically between 20°C and 25°C. It is required to keep the syrup in a cool, dry place, and it must not be frozen or refrigerated. The syrup must be kept in its original container with the cap tightly closed.

Stability and Child Safety

Once the bottle is opened, the product should be discarded after 30 days of initial use. Due to the codeine component, the syrup must be stored out of the sight and reach of children and pets at all times, often necessitating a locked location.

Disposal

Unused or expired medication should be disposed of via an official drug take-back program. If a program is unavailable, follow specific guidelines for controlled substances, which involve mixing the drug with an unappealing substance (like cat litter) before placing it in the household trash. The product must not be poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Euphon (+Codeine) found in:

A-Z Index: